DermatologyPfizer
Pfizer Reports Three-Year JADE MONO Data for Cibinqo in Atopic Dermatitis
BMI
Biotechnology Media Insights
Editorial Team · February 25, 2024
Pfizer presents three-year follow-up data from JADE MONO trials showing sustained skin clearance with Cibinqo monotherapy in moderate-to-severe atopic dermatitis.
Pfizer today presented three-year follow-up data from the Phase 3 JADE MONO-1 and JADE MONO-2 trials evaluating Cibinqo (abrocitinib) monotherapy in patients with moderate-to-severe atopic dermatitis. The data showed that the skin clearance benefits of Cibinqo were maintained over three years of treatment.
BMI
Biotechnology Media Insights
Published by Biotechnology Media Insights — your trusted source for pharmaceutical, biotech, and life sciences news.